Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
53.04%
0%
53.04%
6 Months
1631.2%
0%
1631.2%
1 Year
1354.3%
0%
1354.3%
2 Years
1038.95%
0%
1038.95%
3 Years
1679.61%
0%
1679.61%
4 Years
331.08%
0%
331.08%
5 Years
395.19%
0%
395.19%
Abivax SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-221.82%
EBIT to Interest (avg)
-13.97
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.22
Sales to Capital Employed (avg)
0
Tax Ratio
3.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
33.94%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-100.17
EV to EBIT
-26.20
EV to EBITDA
-26.36
EV to Capital Employed
-189.80
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Bullish
Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-184.30
-131.30
-40.37%
Interest
14.10
15.80
-10.76%
Exceptional Items
-0.80
-1.90
57.89%
Consolidate Net Profit
-176.20
-147.70
-19.30%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -19.30% vs -143.33% in Dec 2023
About Abivax SA 
Abivax SA
Pharmaceuticals & Biotechnology
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Coordinates 
Company Details
5, rue de la Baume, Paris 8 , PARIS None : 75008
Registrar Details






